Barrett-Lee, Peter, Dixon, J. M., Farrell, C., Jones, A., Leonard, R., Murray, N., Palmieri, C., Plummer, C. J., Stanley, A. and Verrill, M. W. 2009. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Annals of Oncology 20 (5) , pp. 816-827. 10.1093/annonc/mdn728 |
Abstract
Anthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Schools > Medicine |
Subjects: | R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology |
Uncontrolled Keywords: | advanced breast cancer; anthracyclines; cardiac monitoring; cardiotoxicity; liposomal anthracyclines; risk factors |
Publisher: | Oxford University Press |
ISSN: | 0923-7534 |
Last Modified: | 10 Oct 2017 14:10 |
URI: | https://orca.cardiff.ac.uk/id/eprint/25613 |
Citation Data
Cited 122 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |